Form 4: Casdin Funds Boost Standard BioTools Stake

Casdin Partners Master Fund and affiliated entities increased their beneficial ownership in Standard BioTools Inc. through open market purchases totaling 1,075,000 shares.

Summary

• Casdin Partners Master Fund, L.P. and affiliated entities, including Casdin Capital, LLC and Eli Casdin, acquired a total of 1,075,000 shares of Standard BioTools Inc. common stock.
• The purchases occurred over three consecutive days: 275,000 shares on November 18, 2025, 350,000 shares on November 19, 2025, and 450,000 shares on November 20, 2025.
• The shares were acquired at weighted average prices of $1.2342, $1.2826, and $1.3028, respectively.
• Following these transactions, Casdin Partners Master Fund, L.P. indirectly beneficially owns 64,050,000 shares.
• Eli Casdin directly owns 2,901,062 shares.
• Casdin Private Growth Equity Fund II, L.P. indirectly owns 13,939,637 shares.
• Casdin Private Growth Equity Fund, L.P. indirectly owns 2,744,219 shares.
• The reporting persons, including Eli Casdin, are identified as both Directors and 10% Owners of Standard BioTools Inc.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to substantial insider buying by a significant shareholder and director, indicating strong belief in the company's value and future performance.

Positives

• Significant insider buying by a 10% owner and director group, indicating strong confidence in the company's future prospects.
• The purchases represent a substantial increase in the beneficial ownership of the reporting persons, reinforcing their commitment to Standard BioTools Inc.

Future Outlook

NA

Management Comments

• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of Standard BioTools Inc.
• By virtue of Mr. Casdin's representation, each of the Reporting Persons may be deemed directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934.

Industry Context

NA

Corporate Governance

Related Party Transactions

• The reported purchases of common stock by Casdin Partners Master Fund, L.P. and its affiliates are considered related party transactions, as the reporting persons are identified as both Directors and 10% Owners of Standard BioTools Inc.

Stakeholder Impact

• Shareholders may view the significant insider buying as a positive indicator, potentially increasing investor confidence and demand for the stock.
• The increased stake by a major investor and director could signal stability and strong oversight to other stakeholders.

Key Dates

Recommendation

The significant open market purchases by Casdin Partners, a 10% owner and a group with director representation, signals strong conviction in Standard BioTools Inc.'s valuation and future prospects. Such substantial insider buying often precedes positive company developments or reflects a belief that the stock is undervalued, making it an attractive buying opportunity for seasoned investors.

Keywords

Standard BioTools, LAB, Casdin Partners, Insider Buying, Form 4, Equity Purchase, 10% Owner, Director, Biotech Investment